Globally, The necessity is biggest in resource-restricted nations around the world with small HIV awareness and lack of education and learning about cure and avoidance alternatives. Considering that 2006, Gilead has entered into voluntary licensing agreements with generic producers in reduced- and middle-income nations around the world that grant them https://www.directivepublications.org/journal-of-hiv-aids-research/